Search | IOVS | ARVO Journals

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Intravitreal Dexamethasone Implant in anti-VEGF Pretreated Diabetic Macular Edema – a Swiss Cohort Study

Ferhat Turgut; Gabor Mark Somfai; Christoph Tappeiner; Katja B Hatz; Irmela Mantel; Aude Ambresin; Guy Donati; Viviane Guignard; Dana Nagyová; Isabel B. Pfister; Christin Schild; Justus G Garweg

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6263.

ARVO Annual Meeting Abstract June 2023

Intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept

Katja B Hatz; Luca Cedro

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):OD80.

ARVO Annual Meeting Abstract June 2022

Disease activity (DA) monitoring in neovascular age-related macular degeneration (nAMD) with artificial intelligence (AI): a feasibility study

Pearse Andrew Keane; Jayashree Sahni; Zufar Mulyukov; Sandra Liakopoulos; Katja Hatz; Daniel Ting Shu Wei; Roberto Gallego Pinazo; Daniel Lorand

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2997 – F0267.

ARVO Annual Meeting Abstract June 2022

Geographic atrophy in AMD - prognostic factors based on long-term follow-up

Katja B Hatz; Laura Hoffmann; Luca Cedro

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):338 – F0169.

ARVO Annual Meeting Abstract June 2021

Efficacy and outcome predictors of long-term intravitreal anti-VEGF therapy in neovascular age-related macular degeneration following a strict treat-and-extend regimen.

Katja B Hatz

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):438.

ARVO Annual Meeting Abstract June 2020

Perfusion characteristics of the optic nerve head and macular region in long-term compared to recently started anti-VEGF treatment

Katja B Hatz; Cengiz Tuerksever

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2644.

ARVO Annual Meeting Abstract July 2019

Intravitreal Aflibercept in a Routine Treat and Extend (T&E) Regimen for Treatment-Naïve wet AMD Patients: 2-Year Outcomes of the observational ASTERIA Study

Andreas Ebneter; Stephan Michels; Pascal Imesch; Felix Eilenberger; Susanne Oesch; Christian Prünte; Katja Hatz

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):95.

ARVO Annual Meeting Abstract July 2019

Microvascular abnormalities, retinal thickness changes and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD

Katja Hatz; Frank Zimmermann; Emmanouil Lazaridis; Dimitrios Kardamakis; Magdalena Guichard; Cengiz Tuerksever; Christian Pruente; Ursula Schmidt-Erfurth; Bianca S Gerendas

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1154.

ARVO Annual Meeting Abstract June 2017

Early retinal changes in Optical Coherence Tomography in patients with type 1 diabetes under intensified insulin therapy

Christian Pruente; Bianca S Gerendas; Katja B Hatz; Ursula Schmidt-Erfurth; Alessio Montuoro; Alexandra Kaider

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):71.

ARVO Annual Meeting Abstract June 2017

Correlation of total HbA1c load with prevalence of diabetic retinopathy among type 1 diabetic patients treated with intensified insulin therapy from the onset of disease

Katja B Hatz; Henryk Zulewski; Bianca S Gerendas; Anna Minder; Ursula Schmidt-Erfurth; Roger Lehmann; Alexandra Kaider; Christian Pruente

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):82.

ARVO Annual Meeting Abstract September 2016

Low energy stereotactic radiotherapy in combination with an anti VEGF treat and extend regimen for treatment of neovascular age related macular degeneration: 12 month outcomes

Katja B Hatz; Frank Zimmermann; Dimitrios Kardamakis; Emmanouil Lazaridis; Cengiz Tuerksever; Christian Pruente

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3692.

Retina March 2016

Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression

PDF

Chantal Dysli; Sebastian Wolf; Katja Hatz; Martin S. Zinkernagel
TAGS: diagnostic imaging, disease progression, fluorescence, stargardt's disease, autofluorescence, atrophic condition of skin
Invest. Ophthalmol. Vis. Sci.. 2016; 57(3):832-841. https://doi.org/10.1167/iovs.15-18033

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2015

Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat and extend trial

Katja B Hatz; Christian Pruente; Vistaklinik Binningen

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4595.

ARVO Annual Meeting Abstract June 2015

A cross sectional study assessing the prevalence of different stages of diabetic retinopathy and diabetic macular edema among type 1 diabetic patients treated with long-term intensified insulin therapy aiming near-normal blood glucose levels

Christian Pruente; Hendryk Zulewski; Ursula Schmidt-Erfurth; Bianca S. Gerendas; Katja B Hatz

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1452.

ARVO Annual Meeting Abstract June 2015

Similar two-year safety profiles of bilateral versus unilateral treatments with ranibizumab 0.5 mg in nAMD and DME

Sergio Pagliarini; Katja B Hatz; Philippe Margaron; Vladimir Bezlyak; Christine Thorburn

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1510.

ARVO Annual Meeting Abstract April 2014

Treat and Extend regimen versus Pro Re Nata regimen in a comparative study of ranibizumab in exudative age-related macular degeneration: 12 months results

Katja B Hatz; Christian Pruente

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3931.

ARVO Annual Meeting Abstract June 2013

Changing from pro re nata treatment regimen to a treat and extend regimen in neovascular age-related macular degeneration

Katja Hatz; Christian Pruente

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3812.

ARVO Annual Meeting Abstract March 2012

Prevalence Of Polypoidal Choroidal Vasculopathy Among Caucasian Bad-responders To Antivegf-treatment In Exudative Amd

Katja B. Hatz; Christian Pruente

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3805.

ARVO Annual Meeting Abstract April 2011

Effect of Intravitreal Anti-VEGF Therapy to Retinal Nonperfusion in Patients treated with Lucentis (Ranibizumab) for Retinal Vein Occlusion

Florian Weisskopf; Christian Pruente; Katja Hatz

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1256.

ARVO Annual Meeting Abstract April 2011

Ranibizumab Treatment for Diabetic Macular Edema in a Clinical Routine Setting: 12 Months Results

Christian Pruente; Katja Hatz

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):563.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Intravitreal Dexamethasone Implant in anti-VEGF Pretreated Diabetic Macular Edema – a Swiss Cohort Study

Intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept

Disease activity (DA) monitoring in neovascular age-related macular degeneration (nAMD) with artificial intelligence (AI): a feasibility study

Geographic atrophy in AMD - prognostic factors based on long-term follow-up

Efficacy and outcome predictors of long-term intravitreal anti-VEGF therapy in neovascular age-related macular degeneration following a strict treat-and-extend regimen.

Perfusion characteristics of the optic nerve head and macular region in long-term compared to recently started anti-VEGF treatment

Intravitreal Aflibercept in a Routine Treat and Extend (T&E) Regimen for Treatment-Naïve wet AMD Patients: 2-Year Outcomes of the observational ASTERIA Study

Microvascular abnormalities, retinal thickness changes and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD

Early retinal changes in Optical Coherence Tomography in patients with type 1 diabetes under intensified insulin therapy

Correlation of total HbA1c load with prevalence of diabetic retinopathy among type 1 diabetic patients treated with intensified insulin therapy from the onset of disease

Low energy stereotactic radiotherapy in combination with an anti VEGF treat and extend regimen for treatment of neovascular age related macular degeneration: 12 month outcomes

Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression

Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat and extend trial

A cross sectional study assessing the prevalence of different stages of diabetic retinopathy and diabetic macular edema among type 1 diabetic patients treated with long-term intensified insulin therapy aiming near-normal blood glucose levels

Similar two-year safety profiles of bilateral versus unilateral treatments with ranibizumab 0.5 mg in nAMD and DME

Treat and Extend regimen versus Pro Re Nata regimen in a comparative study of ranibizumab in exudative age-related macular degeneration: 12 months results

Changing from pro re nata treatment regimen to a treat and extend regimen in neovascular age-related macular degeneration

Prevalence Of Polypoidal Choroidal Vasculopathy Among Caucasian Bad-responders To Antivegf-treatment In Exudative Amd

Effect of Intravitreal Anti-VEGF Therapy to Retinal Nonperfusion in Patients treated with Lucentis (Ranibizumab) for Retinal Vein Occlusion

Ranibizumab Treatment for Diabetic Macular Edema in a Clinical Routine Setting: 12 Months Results

To View More...

You must be signed into an individual account to use this feature.